<DOC>
	<DOCNO>NCT00450970</DOCNO>
	<brief_summary>The SPERA trial design 1. provide satraplatin physicians patient hormone refractory prostate cancer ( HRPC ) progress follow unlimited cytotoxic chemotherapy regimens metastatic disease 2. evaluate safety oral satraplatin patient population .</brief_summary>
	<brief_title>Expanded Access Study Satraplatin Plus Prednisone Patients With Hormone Refractory Prostate Cancer ( HRPC )</brief_title>
	<detailed_description>*****UPDATE***** On October 30th , 2007 GPC Biotech announce topline overall survival result Phase III trial hormone refractory prostate cancer-Satraplatin Prednisone Against Refractory Cancer ( SPARC ) trial . The trial evaluate satraplatin plus prednisone versus placebo plus prednisone second-line treatment 950 patient hormone-refractory prostate cancer ( HRPC ) . The company report trial achieve endpoint overall survival ( p=0.80 , stratify log rank analysis ) . The median 61.3 week satraplatin arm compare 61.4 week control group hazard ratio 0.97 ( 95 % CI : 0.83 , 1.13 ) . The company currently conduct pre-specified subset analysis . Satraplatin member platinum-based class chemotherapy drug . Platinum-based drug clinically prove one effective class anticancer therapy . Unlike currently market platinum-based drug , satraplatin give orally .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>Metastatic ( Stage D2 ) prostate cancer Progression unlimited prior cytotoxic chemotherapy regimens ECOG Performance status equal/less 2 Surgical medical castration Adequate bone marrow , liver , renal function Informed consent Patients treat bisphosphonates prior entry eligible continue bisphosphonates therapy trial Serious concurrent uncontrolled medical disorder Malignant disease require ongoing therapy Prior significant RT/radionuclide therapy Major GI surgery GI disease affect absorption Disease corticosteroid contraindicate Brain metastasis Poorlycontrolled uncontrolled insulindependent diabetes</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Hormone Refractory Prostate Cancer ( HRPC )</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>Unlimited Prior Cytotoxic Chemotherapy Regimens</keyword>
</DOC>